Idec Eyes Success
Executive SummaryTroubles that made Idec drop its lead drug convinced it to take on manufacturing. From a stock price in June 1994 of $2.44 to a stock price of $24 in September 1996, whatever becomes of the products now coming through Idec's pipeline, the strategy that got it out of some bad times is worth a closer look.
You may also be interested in...
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.